B-Cell Lymphomas Clinical Trial
Official title:
Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen (ProDLBCL)
This study is a retrospective analysis of an homogeneous population of patients with aggressive B-cell lymphoma and treated upfront with R-CHOP or R-CHOP like regimens to reassess the prognostic factors and hopefully to identify more accurate prognostic subgroups with a clinical and therapeutical relevance.
n/a
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02891590 -
Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas
|
Phase 1 | |
| Completed |
NCT01068392 -
Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL)
|
Phase 2 | |
| Terminated |
NCT01744912 -
Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies
|
Phase 1 | |
| Completed |
NCT03218072 -
A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas
|
Phase 1 | |
| Withdrawn |
NCT05160064 -
Long-term Registry of Patients Treated With Loncastuximab Tesirine
|
||
| Recruiting |
NCT02247609 -
Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell Lymphomas
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00801216 -
High-Dose Sequential Chemoimmunotherapy for B-Cell Lymphomas With Central Nervous System Involvement
|
Phase 2 | |
| Completed |
NCT01613300 -
Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients
|
Phase 2 | |
| Active, not recruiting |
NCT05773040 -
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
|
Phase 1 |